Correlation of histopathologic characteristics to protein expression and function in malignant melanoma

Charlotte Welinder, Krzysztof Pawøowski, A. Szász, Maria Yakovleva, Yutaka Sugihara, Johan Malm, Göran Jönsson, Christian Ingvar, Lotta Lundgren, Bo Baldetorp, Håkan Olsson, Melinda Rezeli, Thomas Laurell, Elisabet Wieslander, György Marko-Varga

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background Metastatic melanoma is still one of the most prevalent skin cancers, which upon progression has neither a prognostic marker nor a specific and lasting treatment. Proteomic analysis is a versatile approach with high throughput data and results that can be used for characterizing tissue samples. However, such analysis is hampered by the complexity of the disease, heterogeneity of patients, tumors, and samples themselves. With the long term aim of quest for better diagnostics biomarkers, as well as predictive and prognostic markers, we focused on relating high resolution proteomics data to careful histopathological evaluation of the tumor samples and patient survival information. Patients and methods Regional lymph node metastases obtained from ten patients with metastatic melanoma (stage III) were analyzed by histopathology and proteomics using mass spectrometry. Out of the ten patients, six had clinical follow-up data. The protein deep mining mass spectrometry data was related to the histopathology tumor tissue sections adjacent to the area used for deep-mining. Clinical follow-up data provided information on disease progression which could be linked to protein expression aiming to identify tissue-based specific protein markers for metastatic melanoma and prognostic factors for prediction of progression of stage III disease.Results In this feasibility study, several proteins were identified that positively correlated to tumor tissue content including IF6, ARF4, MUC18, UBC12, CSPG4, PCNA, PMEL and MAGD2. The study also identified MYC, HNF4A and TGFB1 as top upstream regulators correlating to tumor tissue content. Other proteins were inversely correlated to tumor tissue content, the most significant being; TENX, EHD2, ZA2G, AOC3, FETUA and THRB. A number of proteins were significantly related to clinical outcome, among these, HEXB, PKM and GPNMB stood out, as hallmarks of processes involved in progression from stage III to stage IV disease and poor survival. Conclusion In this feasibility study, promising results show the feasibility of relating proteomics to histopathology and clinical outcome, and insight thus can be gained into the molecular processes driving the disease. The combined analysis of histological features including the sample cellular composition with protein expression of each metastasis enabled the identification of novel, differentially expressed proteins. Further studies are necessary to determine whether these putative biomarkers can be utilized in diagnostics and prognostic prediction of metastatic melanoma.

Original languageEnglish
Article numbere0176167
JournalPLoS One
Volume12
Issue number4
DOIs
Publication statusPublished - Apr 1 2017

Fingerprint

melanoma
Melanoma
protein synthesis
Tumors
proteomics
neoplasms
Tissue
underground mining
histopathology
Proteomics
Proteins
proteins
metastasis
Neoplasms
biomarkers
Feasibility Studies
Biomarkers
mass spectrometry
Mass spectrometry
sampling

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Welinder, C., Pawøowski, K., Szász, A., Yakovleva, M., Sugihara, Y., Malm, J., ... Marko-Varga, G. (2017). Correlation of histopathologic characteristics to protein expression and function in malignant melanoma. PLoS One, 12(4), [e0176167]. https://doi.org/10.1371/journal.pone.0176167

Correlation of histopathologic characteristics to protein expression and function in malignant melanoma. / Welinder, Charlotte; Pawøowski, Krzysztof; Szász, A.; Yakovleva, Maria; Sugihara, Yutaka; Malm, Johan; Jönsson, Göran; Ingvar, Christian; Lundgren, Lotta; Baldetorp, Bo; Olsson, Håkan; Rezeli, Melinda; Laurell, Thomas; Wieslander, Elisabet; Marko-Varga, György.

In: PLoS One, Vol. 12, No. 4, e0176167, 01.04.2017.

Research output: Contribution to journalArticle

Welinder, C, Pawøowski, K, Szász, A, Yakovleva, M, Sugihara, Y, Malm, J, Jönsson, G, Ingvar, C, Lundgren, L, Baldetorp, B, Olsson, H, Rezeli, M, Laurell, T, Wieslander, E & Marko-Varga, G 2017, 'Correlation of histopathologic characteristics to protein expression and function in malignant melanoma', PLoS One, vol. 12, no. 4, e0176167. https://doi.org/10.1371/journal.pone.0176167
Welinder, Charlotte ; Pawøowski, Krzysztof ; Szász, A. ; Yakovleva, Maria ; Sugihara, Yutaka ; Malm, Johan ; Jönsson, Göran ; Ingvar, Christian ; Lundgren, Lotta ; Baldetorp, Bo ; Olsson, Håkan ; Rezeli, Melinda ; Laurell, Thomas ; Wieslander, Elisabet ; Marko-Varga, György. / Correlation of histopathologic characteristics to protein expression and function in malignant melanoma. In: PLoS One. 2017 ; Vol. 12, No. 4.
@article{fbb8316310434d4bae9f866d591f48ed,
title = "Correlation of histopathologic characteristics to protein expression and function in malignant melanoma",
abstract = "Background Metastatic melanoma is still one of the most prevalent skin cancers, which upon progression has neither a prognostic marker nor a specific and lasting treatment. Proteomic analysis is a versatile approach with high throughput data and results that can be used for characterizing tissue samples. However, such analysis is hampered by the complexity of the disease, heterogeneity of patients, tumors, and samples themselves. With the long term aim of quest for better diagnostics biomarkers, as well as predictive and prognostic markers, we focused on relating high resolution proteomics data to careful histopathological evaluation of the tumor samples and patient survival information. Patients and methods Regional lymph node metastases obtained from ten patients with metastatic melanoma (stage III) were analyzed by histopathology and proteomics using mass spectrometry. Out of the ten patients, six had clinical follow-up data. The protein deep mining mass spectrometry data was related to the histopathology tumor tissue sections adjacent to the area used for deep-mining. Clinical follow-up data provided information on disease progression which could be linked to protein expression aiming to identify tissue-based specific protein markers for metastatic melanoma and prognostic factors for prediction of progression of stage III disease.Results In this feasibility study, several proteins were identified that positively correlated to tumor tissue content including IF6, ARF4, MUC18, UBC12, CSPG4, PCNA, PMEL and MAGD2. The study also identified MYC, HNF4A and TGFB1 as top upstream regulators correlating to tumor tissue content. Other proteins were inversely correlated to tumor tissue content, the most significant being; TENX, EHD2, ZA2G, AOC3, FETUA and THRB. A number of proteins were significantly related to clinical outcome, among these, HEXB, PKM and GPNMB stood out, as hallmarks of processes involved in progression from stage III to stage IV disease and poor survival. Conclusion In this feasibility study, promising results show the feasibility of relating proteomics to histopathology and clinical outcome, and insight thus can be gained into the molecular processes driving the disease. The combined analysis of histological features including the sample cellular composition with protein expression of each metastasis enabled the identification of novel, differentially expressed proteins. Further studies are necessary to determine whether these putative biomarkers can be utilized in diagnostics and prognostic prediction of metastatic melanoma.",
author = "Charlotte Welinder and Krzysztof Paw{\o}owski and A. Sz{\'a}sz and Maria Yakovleva and Yutaka Sugihara and Johan Malm and G{\"o}ran J{\"o}nsson and Christian Ingvar and Lotta Lundgren and Bo Baldetorp and H{\aa}kan Olsson and Melinda Rezeli and Thomas Laurell and Elisabet Wieslander and Gy{\"o}rgy Marko-Varga",
year = "2017",
month = "4",
day = "1",
doi = "10.1371/journal.pone.0176167",
language = "English",
volume = "12",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "4",

}

TY - JOUR

T1 - Correlation of histopathologic characteristics to protein expression and function in malignant melanoma

AU - Welinder, Charlotte

AU - Pawøowski, Krzysztof

AU - Szász, A.

AU - Yakovleva, Maria

AU - Sugihara, Yutaka

AU - Malm, Johan

AU - Jönsson, Göran

AU - Ingvar, Christian

AU - Lundgren, Lotta

AU - Baldetorp, Bo

AU - Olsson, Håkan

AU - Rezeli, Melinda

AU - Laurell, Thomas

AU - Wieslander, Elisabet

AU - Marko-Varga, György

PY - 2017/4/1

Y1 - 2017/4/1

N2 - Background Metastatic melanoma is still one of the most prevalent skin cancers, which upon progression has neither a prognostic marker nor a specific and lasting treatment. Proteomic analysis is a versatile approach with high throughput data and results that can be used for characterizing tissue samples. However, such analysis is hampered by the complexity of the disease, heterogeneity of patients, tumors, and samples themselves. With the long term aim of quest for better diagnostics biomarkers, as well as predictive and prognostic markers, we focused on relating high resolution proteomics data to careful histopathological evaluation of the tumor samples and patient survival information. Patients and methods Regional lymph node metastases obtained from ten patients with metastatic melanoma (stage III) were analyzed by histopathology and proteomics using mass spectrometry. Out of the ten patients, six had clinical follow-up data. The protein deep mining mass spectrometry data was related to the histopathology tumor tissue sections adjacent to the area used for deep-mining. Clinical follow-up data provided information on disease progression which could be linked to protein expression aiming to identify tissue-based specific protein markers for metastatic melanoma and prognostic factors for prediction of progression of stage III disease.Results In this feasibility study, several proteins were identified that positively correlated to tumor tissue content including IF6, ARF4, MUC18, UBC12, CSPG4, PCNA, PMEL and MAGD2. The study also identified MYC, HNF4A and TGFB1 as top upstream regulators correlating to tumor tissue content. Other proteins were inversely correlated to tumor tissue content, the most significant being; TENX, EHD2, ZA2G, AOC3, FETUA and THRB. A number of proteins were significantly related to clinical outcome, among these, HEXB, PKM and GPNMB stood out, as hallmarks of processes involved in progression from stage III to stage IV disease and poor survival. Conclusion In this feasibility study, promising results show the feasibility of relating proteomics to histopathology and clinical outcome, and insight thus can be gained into the molecular processes driving the disease. The combined analysis of histological features including the sample cellular composition with protein expression of each metastasis enabled the identification of novel, differentially expressed proteins. Further studies are necessary to determine whether these putative biomarkers can be utilized in diagnostics and prognostic prediction of metastatic melanoma.

AB - Background Metastatic melanoma is still one of the most prevalent skin cancers, which upon progression has neither a prognostic marker nor a specific and lasting treatment. Proteomic analysis is a versatile approach with high throughput data and results that can be used for characterizing tissue samples. However, such analysis is hampered by the complexity of the disease, heterogeneity of patients, tumors, and samples themselves. With the long term aim of quest for better diagnostics biomarkers, as well as predictive and prognostic markers, we focused on relating high resolution proteomics data to careful histopathological evaluation of the tumor samples and patient survival information. Patients and methods Regional lymph node metastases obtained from ten patients with metastatic melanoma (stage III) were analyzed by histopathology and proteomics using mass spectrometry. Out of the ten patients, six had clinical follow-up data. The protein deep mining mass spectrometry data was related to the histopathology tumor tissue sections adjacent to the area used for deep-mining. Clinical follow-up data provided information on disease progression which could be linked to protein expression aiming to identify tissue-based specific protein markers for metastatic melanoma and prognostic factors for prediction of progression of stage III disease.Results In this feasibility study, several proteins were identified that positively correlated to tumor tissue content including IF6, ARF4, MUC18, UBC12, CSPG4, PCNA, PMEL and MAGD2. The study also identified MYC, HNF4A and TGFB1 as top upstream regulators correlating to tumor tissue content. Other proteins were inversely correlated to tumor tissue content, the most significant being; TENX, EHD2, ZA2G, AOC3, FETUA and THRB. A number of proteins were significantly related to clinical outcome, among these, HEXB, PKM and GPNMB stood out, as hallmarks of processes involved in progression from stage III to stage IV disease and poor survival. Conclusion In this feasibility study, promising results show the feasibility of relating proteomics to histopathology and clinical outcome, and insight thus can be gained into the molecular processes driving the disease. The combined analysis of histological features including the sample cellular composition with protein expression of each metastasis enabled the identification of novel, differentially expressed proteins. Further studies are necessary to determine whether these putative biomarkers can be utilized in diagnostics and prognostic prediction of metastatic melanoma.

UR - http://www.scopus.com/inward/record.url?scp=85018180661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85018180661&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0176167

DO - 10.1371/journal.pone.0176167

M3 - Article

C2 - 28445515

AN - SCOPUS:85018180661

VL - 12

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 4

M1 - e0176167

ER -